Toward an understanding of changes in diversity associated with fecal microbiome transplantation based on 16s rRNA gene deep sequencing

mBio

Volumn 3, Issue 5, 2012, Pages

  Low, Donald E ^a   Shahinas, Dea ^b   Silverman, Michael ^c   Sittler, Taylor ^c   Chiu, Charles ^d   Kim, Peter ^d   Allen Vercoe, Emma ^e   Weese, Scott ^f   Wong, Andrew ^a,g,h   Pillaij, Dylan R ⁱ  

^a UNIVERSITY OF TORONTO   (Canada)

^b LAKERIDGE HEALTH CORPORATION   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF GUELPH   (Canada)

^e UNIVERSITY OF GUELPH   (Canada)

^f QUEEN S UNIVERSITY   (Canada)

^g MOUNT SINAI HOSPITAL   (Canada)

^h PUBLIC HEALTH ONTARIO   (Canada)

ⁱ UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84868361276     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00338-12     Document Type: Article

References (52)

1. Lavallée C, et al. 2009. Fatal Clostridium difficile enteritis caused by the BI/NAP1/027 strain: a case series of ileal C. difficile infections. Clin. Mi-crobiol. Infect. 15:1093-1099.
2. O'Connor JR, Johnson S, Gerding DN. 2009. Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. Gastroenterology 136: 1913-1924.
3. Quesada-Gómez C, et al. 2010. Emergence of Clostridium difficile NAP1 in Latin America. J. Clin. Microbiol. 48:669-670.
4. Miller M, et al. 2010. Health care-associated Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality. Clin. Infect. Dis. 50:194-201.
5. Pillai DR, Longtin J, Low DE. 2010. Surveillance data on outbreaks of Clostridium difficile infection in Ontario, Canada, in 2008-2009. Clin. Infect. Dis. 50:1685-1686. (Reply) doi: 10.1086/653007.
6. Cohen SH, et al. 2010. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect. Control Hosp. Epidemiol. 31:431-455.
7. Louie TJ, et al. 2011. Fidaxomicin versus vancomycin for Clostridium difficile infection. N. Engl. J. Med. 364:422-431.
8. Bakken JS. 2009. Fecal bacteriotherapy for recurrent Clostridium difficile infection. Anaerobe 15:285-289.
9. Bowden TA, Jr, Mansberger AR, Jr, Lykins LE. 1981. Pseudomembra-neous enterocolitis: mechanism for restoring floral homeostasis. Am. Surg. 47:178-183.
10. Eiseman B, Silen W, Bascom GS, Kauvar AJ. 1958. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 44:854-859.
11. Grehan MJ, et al. 2010. Durable alteration of the colonic microbiota by the administration ofdonor fecalflora. J. Clin. Gastroenterol. 44:551-561.
12. Khoruts A, Dicksved J, Jansson JK, Sadowsky MJ. 2010. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J. Clin. Gastroenterol. 44:354-360.
13. Schwan A, Sjölin S, Trottestam U, Aronsson B. 1983. Relapsing Clos-tridium difficile enterocolitis cured by rectal infusion of homologous faeces. Lancet ii:845.
14. Silverman MS, Davis I, Pillai DR. 2010. Success of self-administered home fecal transplantation for chronic Clostridium difficile infection. Clin. Gastroenterol. Hepatol. 8:471-473.
15. Zimmer C. 12 July 2010. How microbes defend and define us. N. Y. Times. http://www.nytimes.com/2010/07/13/science/13micro.html?pagewanted =all&_r=0.
16. Von Blech J. 5 March 2011. Heilsamer Stuhl: Im Kampf gegen chronis-chen Durchfall erzielen Arzte Erfolge: Sie pflanzen den Patienten die Darm-bakterien gesunder Spender ein. Der Spiegel. http://www.spiegel.de/spiegel/print/d-77299777.html.
17. Walker EP. 27 January. 2011. The enema of your enemy is your friend. Fecal transplants could be a cheap and effective treatment for gastrointestinal disorders. Slate. http://www.slate.com/articles/health_and_science /medical_examiner/2011/01/the_enema_of_your_enemy_is_your_friend.html.
18. Chang JY, et al. 2008. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J. Infect. Dis. 197: 435-438.
19. Dethlefsen L, Huse S, Sogin ML, Relman DA. 2008. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol. 6:e280. http://dx.doi.org/10.1371/journal.pbio.0060280.
20. Eckburg PB, et al. 2005. Diversity of the human intestinal microbial flora. Science 308:1635-1638.
21. Huse SM, et al. 2008. Exploring microbial diversity and taxonomy using SSU rRNA hypervariable tag sequencing. PLoS Genet. 4:e1000255.http: //dx.doi.org/10.1371/journal.pgen.1000255.
22. Sogin ML, et al. 2006. Microbial diversity in the deep sea and the under-explored "rare biosphere." Proc. Natl. Acad. Sci. U. S. A. 103: 12115-12120.
23. Turnbaugh PJ, et al. 2009. A core gut microbiome in obese and lean twins. Nature 457:480-484.
24. Reid G, Jass J, Sebulsky MT, McCormick JK. 2003. Potential uses of probiotics in clinical practice. Clin. Microbiol. Rev. 16:658-672.
25. Schloss PD, et al. 2009. Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl. Environ. Microbiol. 75:7537-7541.
26. Cole JR, et al. 2007. The ribosomal database project (RDP-II): introducing myRDP space and quality controlled public data. Nucleic Acids Res. 35:D169-D172.
27. Cole JR, et al. 2009. The ribosomal database project: improved alignments and new tools for rRNA analysis. Nucleic Acids Res. 37: D141-D14510.1093/nar/gkp353.PubMed.
28. Meyer F, et al. 2008. The metagenomics RAST server-a public resource for the automatic phylogenetic and functional analysis of metagenomes. BMC Bioinformatics 9:386.http://dx.doi.org/10.1186/1471-2105-9-386.
29. Storey JD, Dai JY, Leek JT. 2007. The optimal discovery procedure for large-scale significance testing, with applications to comparative microar-ray experiments. Biostatistics 8:414-432.
30. Woo S, Leek JT, Storey JD. 2011. A computationally efficient modular optimal discovery procedure. Bioinformatics 27:509-515.
31. Claesson MJ, et al. 2010. Comparison of two next-generation sequencing technologies for resolving highly complex microbiota composition using tandem variable 16S rRNA gene regions. Nucleic Acids Res. 38:e200.http: //dx.doi.org/10.1093/nar/gkq873.
32. Costello EK, et al. 2009. Bacterial community variation in human body habitats across space and time. Science 326:1694-1697.
33. Duncan SH, et al. 2004. Contribution of acetate to butyrate formation by human faecal bacteria. Br. J. Nutr. 91:915-923.
34. Duncan SH, Louis P, Flint HJ. 2004. Lactate-utilizing bacteria, isolated from human feces, that produce butyrate as a major fermentation product. Appl. Environ. Microbiol. 70:5810-5817.
35. Guilloteau P, et al. 2010. From the gut to the peripheral tissues: the multiple effects of butyrate. Nutr. Res. Rev. 23:366-384.
36. Guilloteau P, et al. 2010. Dietary sodium butyrate supplementation increases digestibility and pancreatic secretion in young milk-fed calves. J. Dairy Sci. 93:5842-5850.
37. Guilloteau P, et al. 2009. Sodium-butyrate as a growth promoter in milk replacer formula for young calves. J. Dairy Sci. 92:1038-1049.
38. Costa MC, et al. 2012. Comparison of the fecal microbiota of healthy horses and horses with colitisbyhigh throughput sequencingofthe V3-V5 region of the 16S rRNA gene. PLoS One 7:e41484.http://dx.doi.org/10.1371/journal.pone.0041484.
39. Duncan SH, et al. 2007. Reduced dietary intake of carbohydrates by obese subjects results in decreased concentrations of butyrate and butyrate-producing bacteria in feces. Appl. Environ. Microbiol. 73:1073-1078.
40. Woodcock JM, Andrews JM, Boswell FJ, Brenwald NP, Wise R. 1997. In vitro activity ofBAY 12-8039, a new fluoroquinolone. Antimicrob. Agents Chemother. 41:101-106.
41. Tannock GW, et al. 2010. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology 156: 3354-3359.
42. Finegold SM, et al. 2004. In vitro activity of ramoplanin and comparator drugs against anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora. Anaerobe 10:205-211.
43. Manges AR, et al. 2010. Comparative metagenomic study of alterations to the intestinal microbiota and risk of nosocomial Clostridium difficile-associated disease. J. Infect. Dis. 202:1877-1884.
44. Bäckhed F, et al. 2004. The gut microbiota as an environmental factor that regulates fat storage. Proc. Natl. Acad. Sci. U. S. A. 101:15718-15723.
45. Ley RE, et al. 2005. Obesity alters gut microbial ecology. Proc. Natl. Acad. Sci. U. S. A. 102:11070-11075.
46. Goldstein EJ, et al. 2006. In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections. Antimicrob. Agents Chemother. 50:148-155.
47. McDonald LC, et al. 2005. An epidemic, toxin gene-variant strain of Clostridium difficile. N. Engl. J. Med. 353:2433-2441.
48. Wang Y, Qian PY. 2009. Conservative fragments in bacterial 16S rRNA genes and primer design for 16S ribosomal DNA amplicons in metag-enomic studies. PLoS One 4:e7401. http://dx.doi.org/10.1371/journal.pone.0007401.
49. Pruesse E, et al. 2007. SILVA: a comprehensive online resource for quality checked and aligned ribosomal RNA sequence data compatible with ARB. Nucleic Acids Res. 35:7188-719610.1093/nar/gkm864.PubMed.
50. Bäckhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI. 2005. Host-bacterial mutualisminthe human intestine. Science 307:1915-1920.
51. Ley RE, Peterson DA, Gordon JI. 2006. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell 124: 837-848.
52. Flint HJ, Bayer EA, Rincon MT, Lamed R, White BA. 2008. Polysac-charide utilization by gut bacteria: potential for new insights from genomic analysis. Nat. Rev. Microbiol. 6:121-131.